JP2019534044A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534044A5 JP2019534044A5 JP2019545717A JP2019545717A JP2019534044A5 JP 2019534044 A5 JP2019534044 A5 JP 2019534044A5 JP 2019545717 A JP2019545717 A JP 2019545717A JP 2019545717 A JP2019545717 A JP 2019545717A JP 2019534044 A5 JP2019534044 A5 JP 2019534044A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- amino acid
- antibody
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022087695A JP7455897B2 (ja) | 2016-11-08 | 2022-05-30 | 抗ｐｄ１および抗ｃｔｌａ４抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662419157P | 2016-11-08 | 2016-11-08 | |
| US62/419,157 | 2016-11-08 | ||
| PCT/US2017/060122 WO2018089293A2 (en) | 2016-11-08 | 2017-11-06 | Anti-pd1 and anti-ctla4 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022087695A Division JP7455897B2 (ja) | 2016-11-08 | 2022-05-30 | 抗ｐｄ１および抗ｃｔｌａ４抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019534044A JP2019534044A (ja) | 2019-11-28 |
| JP2019534044A5 true JP2019534044A5 (enExample) | 2021-02-12 |
Family
ID=60409406
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019545717A Pending JP2019534044A (ja) | 2016-11-08 | 2017-11-06 | 抗ｐｄ１および抗ｃｔｌａ４抗体 |
| JP2022087695A Active JP7455897B2 (ja) | 2016-11-08 | 2022-05-30 | 抗ｐｄ１および抗ｃｔｌａ４抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022087695A Active JP7455897B2 (ja) | 2016-11-08 | 2022-05-30 | 抗ｐｄ１および抗ｃｔｌａ４抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11124570B2 (enExample) |
| EP (1) | EP3538137A2 (enExample) |
| JP (2) | JP2019534044A (enExample) |
| CN (2) | CN118480125A (enExample) |
| AU (1) | AU2017356860A1 (enExample) |
| CA (1) | CA3042249A1 (enExample) |
| WO (1) | WO2018089293A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109475627B (zh) * | 2016-05-26 | 2023-01-06 | 齐鲁普吉湾生物治疗公司 | 抗体混合物 |
| JP2019534044A (ja) | 2016-11-08 | 2019-11-28 | クイル ピュージェット サウンド バイオセラピューティクス コーポレーション | 抗ｐｄ１および抗ｃｔｌａ４抗体 |
| US20220056481A1 (en) * | 2018-12-28 | 2022-02-24 | Transgene | M2-defective poxvirus |
| WO2020180811A1 (en) | 2019-03-04 | 2020-09-10 | Qilu Puget Sound Biotherapeutics Corporation | Anti-sirp-alpha antibodies |
| WO2021041678A1 (en) | 2019-08-30 | 2021-03-04 | Qilu Puget Sound Biotherapeutics Corporation | Anti-cd20 antibodies, anti-cd37 antibodies, and mixtures thereof |
| EP4134377A4 (en) * | 2020-05-06 | 2024-05-15 | Korea University Research and Business Foundation | PD-1 VARIANTS WITH INCREASED PD-L1 AFFINITY |
| CN111875697B (zh) * | 2020-08-03 | 2021-10-01 | 杭州皓阳生物技术有限公司 | 一种包含肽标签的融合蛋白 |
| WO2022178319A1 (en) * | 2021-02-18 | 2022-08-25 | Qilu Puget Sound Biotherapeutics Corporation | Combinations of anti-pd1 and anti-ctla4 antibodies |
| CN118660720A (zh) * | 2022-02-22 | 2024-09-17 | 齐鲁制药有限公司 | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 |
| WO2023185720A1 (zh) * | 2022-03-28 | 2023-10-05 | 齐鲁制药有限公司 | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 |
| WO2023198089A1 (zh) * | 2022-04-13 | 2023-10-19 | 齐鲁制药有限公司 | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 |
| WO2023240086A1 (en) * | 2022-06-07 | 2023-12-14 | Unm Rainforest Innovations | Humanized non-opioid composition and therapies for pain management |
| US20250376525A1 (en) * | 2022-06-28 | 2025-12-11 | Qilu Pharmaceutical Co., Ltd. | Pharmaceutical composition comprising mixed antibody of anti-ctla4 and anti-pd1 and therapeutic use thereof |
| EP4548930A4 (en) * | 2022-06-30 | 2025-10-22 | Qilu Pharmaceutical Co Ltd | PHARMACEUTICAL COMPOSITION COMPRISING A MIXTURE OF ANTI-CTLA4 AND ANTI-PD1 ANTIBODIES AND ITS THERAPEUTIC USE |
| TW202525861A (zh) * | 2023-12-01 | 2025-07-01 | 大陸商齊魯製藥有限公司 | 穩定的混合抗體的藥物組合物 |
| WO2025228542A1 (en) | 2024-05-03 | 2025-11-06 | Genmab B.V. | Method for co-expression of a plurality of antibodies |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07507055A (ja) | 1992-02-26 | 1995-08-03 | アラーガン、インコーポレイテッド | 眼の創傷の治癒における血小板誘導化成長因子の使用 |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| CZ302706B6 (cs) * | 1998-12-23 | 2011-09-14 | Pfizer Inc. | Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| EP1212422B1 (en) * | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| GB0514779D0 (en) | 2005-07-19 | 2005-08-24 | Celltech R&D Ltd | Biological products |
| WO2007113648A2 (en) * | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー／エス | 二重特異性抗体の生産 |
| BR122017025062B8 (pt) * | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| JP6157046B2 (ja) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法 |
| WO2009100140A1 (en) * | 2008-02-04 | 2009-08-13 | Medarex, Inc. | Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof |
| US20090311187A1 (en) * | 2008-05-29 | 2009-12-17 | Bristol-Myers Squibb Company | Methods for predicting patient response to modulation of the Co-stimulatory pathway |
| JO3246B1 (ar) | 2009-09-09 | 2018-03-08 | Regeneron Pharma | اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري |
| WO2011045704A1 (en) * | 2009-10-12 | 2011-04-21 | Pfizer Inc. | Cancer treatment |
| CA2813796C (en) | 2010-10-18 | 2019-01-15 | Mediapharma S.R.L. | Erbb3 binding antibody |
| IN2013MN01438A (enExample) | 2011-03-17 | 2015-06-12 | Univ Ramot | |
| CN202105787U (zh) | 2011-06-03 | 2012-01-11 | 杨自强 | 糠粞分离机 |
| MX368257B (es) | 2011-08-01 | 2019-09-26 | Genentech Inc | Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer. |
| CN102851338A (zh) | 2012-07-25 | 2013-01-02 | 苏州康宁杰瑞生物科技有限公司 | 利用电荷排斥作用制备同二聚体蛋白混合物的方法 |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| US10118971B2 (en) | 2013-03-13 | 2018-11-06 | Ibentrus, Inc. | Protein in which electrical interaction is introduced within hydrophobic interaction site and preparation method therefor |
| SG10201804945WA (en) * | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| IL260021B (en) * | 2015-12-14 | 2022-09-01 | Macrogenics Inc | Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them |
| JP2019534044A (ja) | 2016-11-08 | 2019-11-28 | クイル ピュージェット サウンド バイオセラピューティクス コーポレーション | 抗ｐｄ１および抗ｃｔｌａ４抗体 |
-
2017
- 2017-11-06 JP JP2019545717A patent/JP2019534044A/ja active Pending
- 2017-11-06 AU AU2017356860A patent/AU2017356860A1/en not_active Abandoned
- 2017-11-06 US US16/347,554 patent/US11124570B2/en active Active
- 2017-11-06 EP EP17801203.5A patent/EP3538137A2/en active Pending
- 2017-11-06 CN CN202410423333.9A patent/CN118480125A/zh active Pending
- 2017-11-06 CA CA3042249A patent/CA3042249A1/en active Pending
- 2017-11-06 CN CN201780069181.5A patent/CN110312523B/zh active Active
- 2017-11-06 WO PCT/US2017/060122 patent/WO2018089293A2/en not_active Ceased
-
2021
- 2021-09-16 US US17/477,525 patent/US12037397B2/en active Active
-
2022
- 2022-05-30 JP JP2022087695A patent/JP7455897B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534044A5 (enExample) | ||
| ES2777603T3 (es) | Anticuerpos PD-L1 ("ligando de muerte programada 1") | |
| JP2020516240A5 (enExample) | ||
| JP2018527919A5 (enExample) | ||
| RU2018134065A (ru) | Антитела, специфические к рецептору полиовируса (pvr) человека | |
| JP2017532952A5 (enExample) | ||
| KR102104296B1 (ko) | 종양성 질병들에 대한 치료 | |
| JP2025065211A (ja) | 癌の治療における有効性の増強のためのｐｄ－１阻害剤とｌａｇ－３阻害剤の組み合わせ | |
| FI3459597T3 (fi) | Yksiketjuinen vasta-aine ctla4:lle ja siitä johdettu proteiini | |
| RU2019104980A (ru) | Анти-icos антитела | |
| CN102753195A (zh) | 用于增强抗肿瘤抗体疗法的方法 | |
| JP2019528683A5 (enExample) | ||
| JP2018532383A5 (enExample) | ||
| US12570757B2 (en) | Antibodies against the poliovirus receptor (PVR) and uses thereof | |
| JP2022532173A5 (enExample) | ||
| JP2022553922A5 (enExample) | ||
| AU2020207664A1 (en) | Antibodies specific to human Nectin-2 | |
| JP2022516071A5 (enExample) | ||
| CN113412124A (zh) | Baff-r双特异性t细胞衔接子抗体 | |
| JP2023553210A5 (enExample) | ||
| JP2022517216A5 (enExample) | ||
| CA3062479A1 (en) | Bispecific recombinant protein and use thereof | |
| CN113501879B (zh) | 一种解除肿瘤免疫微环境中免疫抑制的双功能抗体及其应用和制备方法 | |
| IL277899B1 (en) | Methods and compositions for treating yellow fever | |
| CN106963950B (zh) | 用于治疗肿瘤的联合用药物 |